Mackenzie Financial 13F: Adds $1.5M to ABT Stake
Mackenzie Financial has raised its position in Abbott Laboratories by 16,002 shares, reflecting a 1.1% increase.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mackenzie Financial added 16,002 shares to its stake in Abbott Laboratories ($ABT), a 1.10% increase, according to a 13F filing with the SEC dated May 13, 2026. It reported 1,473,375 shares worth $137.12 million at the end of the quarter.
Since the filing, $ABT is up 5.4% after 1 week, up 5.2% after 1 month and up 26.8% to date (from the $82.73 close on May 13, 2026).
Find the original: Mackenzie Financial 13F filings on SEC EDGAR
ABT
Abbott Laboratories
Key Points
- Mackenzie Financial boosted its stake in Abbott Laboratories by 16,002 shares, bringing its total to 1,473,375 shares valued at about $137.1 million as of May 13, 2026.
- Abbott Laboratories shares traded at $93.06 on the day of the filing, down from a previous close of $102.34, and are currently well below their 52-week high of $132.03.
- Analysts remain optimistic, with TD Cowen reiterating a Buy rating and a $135 price target on October 16, 2026.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Mackenzie Financial Boosts Position in Abbott Laboratories
Mackenzie Financial has increased its stake in Abbott Laboratories (NYSE: ABT) by 16,002 shares, bringing its total holdings to 1,473,375 shares. This change reflects a 1.1% increase in their position, with the reported value now at approximately $137.1 million as of May 13, 2026, according to the latest Form 13F filing with the SEC.
Mackenzie Financial vs. the S&P 500
Hypothetical returns from Mackenzie Financial's disclosed trades, not real profit or advice. How we model this.
Recent Changes in Mackenzie Financial's Holdings
This adjustment marks a continued investment strategy for Mackenzie Financial, which has shown confidence in Abbott's potential. The fund's previous share count was 1,457,373, making this a notable addition to their portfolio.
Institutional Activity Around Abbott
No other funds reported changes in their positions regarding Abbott Laboratories, highlighting Mackenzie Financial's unique move in the recent filings. This could suggest a divergence in investment strategies among peers in the healthcare sector, particularly in the medical devices industry.
Stock Performance and Market Context
Abbott Laboratories shares traded at $93.06 on the day of the filing. This price is significantly lower than its 52-week high of $132.03, indicating a potential buying opportunity for some investors. The stock has seen fluctuations, with a recent close of $102.34, suggesting it has been under pressure.
Analysts Set New Price Targets
On October 16, 2026, TD Cowen reiterated its Buy rating for Abbott Laboratories, maintaining a price target of $135. Barclays initiated coverage with an Overweight rating and a $120 target on October 7, 2026. Rothschild & Co upgraded its rating to Buy with a target of $127. These ratings reflect a strong consensus among analysts, who generally view Abbott positively, with a mean target price of $120.71 from 26 analysts.
What Abbott Laboratories Does
Abbott Laboratories, based in Abbott Park, Illinois, specializes in health care products across four segments: pharmaceuticals, diagnostics, nutrition, and medical devices. The company continues to innovate and expand its product offerings, which is crucial for maintaining its market position.
What to Watch at Abbott Laboratories
Investors will be looking ahead to Abbott Laboratories' next earnings report, scheduled for October 21, 2026. As this filing reflects holdings as of May 13, 2026, it may not represent Mackenzie Financial's current position. Further filings and analyst updates will be important to monitor as the market evolves.
Related Filing Alerts
Source: Mackenzie Financial's 13F filing on $ABT (May 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Mackenzie Financial 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts